Raymond James Financial Inc. Invests $14.90 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James Financial Inc. bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 161,708 shares of the medical instruments supplier's stock, valued at approximately $14,900,000. Raymond James Financial Inc. owned approximately 0.72% of LeMaitre Vascular at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. New York State Teachers Retirement System increased its holdings in LeMaitre Vascular by 1.2% in the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after buying an additional 100 shares in the last quarter. Flputnam Investment Management Co. boosted its position in LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC grew its holdings in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC increased its position in shares of LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after buying an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH raised its stake in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock worth $1,285,000 after buying an additional 112 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of research analyst reports. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital lifted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.25.

LeMaitre Vascular Price Performance

Shares of LMAT traded down $0.15 during mid-day trading on Friday, reaching $91.61. The stock had a trading volume of 106,920 shares, compared to its average volume of 161,598. The business's fifty day moving average is $86.90 and its 200 day moving average is $93.42. LeMaitre Vascular, Inc. has a 52-week low of $64.27 and a 52-week high of $109.58. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.87%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.